63 results about "Peripheral Blood Stem Cells" patented technology

Methods of ex-vivo expansion of fetal and / or adult progenitor, and umbilical cord blood, bone marrow or peripheral blood derived stem cells in bioreactors for bone marrow transplantation, transfusion medicine, regenerative medicine and gene therapy.

The present invention relates to methods, kits and compositions for expansion of hematopoietic stem / progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem / progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem / progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem / progenitor cells, placental cord blood stem / progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem / progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and / or long-term in vivo repopulation benefits.

The invention provides methods of treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s).

An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or "pre-disease" state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells.

The invention relates to a medical dressing with bioactivity and a preparation method of the medical dressing and belongs to the technical field of biomedical engineering and material science. The medical dressing with the bioactivity is used for covering skin defect wounds caused by burning, scalding, operation, wounds and diseases and inducing wound repair and is prepared as follows: one or more of embryonic stem cells, umbilical cord blood stem cells, amniotic fluid stem cells, peripheral blood stem cells and bone mesenchymal stem cells of humans or animals are cultured in vitro, stem cell growth factors secreted in the logarithmic growth phase are collected and mixed in proportion with one or more of I type collagen, III type collagen, chitosan, hyaluronic acid, chondroitin sulfate and sodium alginate, thin-layer sponge is taken as an inner layer, a porous high-polymer material film outer layer prepared from a mixture formed by one or more of PLA (polylactic acid), PGA (polyglycolic acid), PLGA (poly(lactic-co-glycolic acid)) and PCL (polycaprolactone) is attached, the product is frozen-dried and cut, and the medical dressing with the bioactivity is formed and used for treating skin defect wounds caused by burning, scalding, operation, wounds and diseases and inducing wound repairing.

The invention relates to the technical field of stem cells and in particular relates to a peripheral blood stem cell preserving fluid. The peripheral blood stem cell preserving fluid comprises the following components in parts by weight: 3-8 parts of human serum albumin, 2-4 parts of trehalose, 1-3 parts of hydroxyethyl starch, 5-15 parts of nutrients, 1-3 parts of dextran, 1-3 parts of dimethyl sulfoxide and a proper amount of water. The preserving liquid is used to preserve the peripheral blood stem cells, so that the stem cells keep relatively good stability and the survival rates of the stem cells are greatly increased (over 98%).

Stem cells are mobilized into the peripheral blood by a method comprising the steps of: (i) administering to an individual at least one of the following: FGF1 and FGF2, and also at least one of the following: VEGF, VEGFA, VEGFB, PLGF, VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206; (ii) isolating the peripheral blood stem cells (PBSC) by apheresis; and (iii) treating a patient suffering from organ disease with PBSC. Alternatively, gene therapy is used for the induction of the stem cells into the peripheral blood, wherein the gene therapy formulation comprises AD5FGF-4 or VEGF165 plasmid DNA. Additionally, the progress of the treatment of the organ disease is monitored by using an ultrasound unit.

The present invention is a tissue engineering skin containing the peripheral blood stem cell and the preparation method. The present invention puts the peripheral blood stem cell and the skin fibroblast cell inside the biological frame. The active tissue engineering skin containing the peripheral blood stem cell is built by planting the epidermal cell on the surface. The tissue engineering skin is similar to the natural skin tissue in structure. Compared with the present skin replacing product, the present invention has properties of improving the blood supply in the wound and promoting the wound healing. The present invention can improve the elastic and toughness properties of the skin as well as the mechanical wear tolerance. The present invention can also reduce the scar proliferation and improve the healing quality. The present invention can improve the success rate of the artificial skin planting and can be effectively applied in repairing the skin defect, which is hard to heal.

The invention relates to a kit for processing human marrow, cord blood and peripheral blood stem cells and a stem cell processing method. The kit radically solves the problems of high manufacture cost, low cell activity, indefinite reaction of markers in a human body, mobilizing agent injection causing patient pain, long obtainment time, complication, clinical unsuitability, and the like in the prior cell separation technology. The invention has the technical scheme that the kit comprises the following three reagents: (1) a diluent comprising 0.9 percent of sodium chloride injection or PBS solution, (2) a precipitator comprising 6 percent of hydroxyethyl starch or 0.2-1 percent of methyl cellulose and (3) a separating solution which has the density of 1.074-1.076 and is prepared by saccharosan and diatrizoate. The kit is easy to store and transport and convenient and rapid to use and can be produced in industrialization.

The present invention is directed to the TVEMF-expansion of mammalian peripheral blood stem cells, preferably CD34+ / CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions.

An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or “pre-disease” state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells.

The invention relates to the field of stem cell culture, and particularly relates to a purpose of umbilical cord mesenchymal stem cell exosome. Shown by experiments, with respect to culture experiments adopting a complete medium, by adopting co-culture of the umbilical cord mesenchymal stem cell exosome and peripheral blood stem cells, the amount of cells acquired by culture can be increased by about 1.5 times, and a clone formation amount is also increased by about 1.5 times. Through statistical analysis, compared with a culture effect without the umbilical cord mesenchymal stem cell exosome, the experiment effect with addition of the umbilical cord mesenchymal stem cell exosome has an extremely remarkable difference (p is smaller than 0.001).

The invention relates to preparation and an application method of a human peripheral blood stem cell freezing medium. The stem cell freezing medium is prepared from the following components in percentage by volume: 48.2% of hydroxyethyl starch dextran, 2% of compound amino acid injection (18AA-IV), 4.8% of dimethyl sulfoxide and 20% of human serum albumin. The stem cell freezing medium has the characteristics of high viable rate after recovery (greater than 99%) and availability for vein back transfusion. The invention further provides the preparation and the application method of the human peripheral blood stem cell freezing medium. The preparation comprises the following steps: under sterile environment, premixing all the components of the human peripheral blood stem cell freezing medium in sequence, adding a stem cell suspension, mixing uniformly, and packing into a cryopreservation bag for cryopreservation. Stem cells with the freezing medium can be directly placed into a cryogenic refrigerator at -80 DEG C for storage, a programmable cooler is not needed, the operation is simple and convenient, and the use is safe.

In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.

The present invention is directed to the process of preparing an expanded peripheral blood stem cell composition, preparing a TVEMF-expanded peripheral blood stem cell composition, methods of producing the same, and to repair of tissue and / or function with expanded, and TVEMF-expanded, peripheral blood stem cells.

A herbal medicinal composition and a herbal medicinal extract for inducing production of peripheral blood stem cells and a method for preparing the same. The herbal medicinal composition contains herbal medicinal herbs disclosed herein such as Cinnamomum Ramulus, Paeoniae (Ovatae) Radix Rubra, Glycyrrhizae Radix, Zingiberis Rhizoma, Jujubae Fructus, Anelicae Radix, and Astragali Radix.

This application relates to stem cell compositions and methods for restoring age-related tissue loss in the face and other selected areas of the body. In a first embodiment, a composition includes stem cells and hyaluronic acid as a carrier wherein the stem cells are peripheral blood stem cells, bone marrow-derived blood stem cells, or mesenchymal stem cells.

The present invention provides a simple, economical yet efficient method of creating transplant tolerance in organ transplant patients without the continuous need for costly immunosuppressive drugs with serious adverse effects. The invention essentially deals with the administration of a novel composition to the patient which consists of adipose tissue derived Mesenchymal Stem Cells (MSC) combined with bone marrow derived Haematopoietic Stem Cells(HSC) and MSC and peripheral blood stem cells (PBSC). This helps in creating transplant tolerance ie. Stable adequate allograft function with minimum / no rejection using very low dose of immunosuppressive medication. The invention also deals with a simple method of isolating Mesenchymal Stem cells from human adipose tissue without using any xenogenic material.

The present invention relates to the field of hematopoietic stem cells. More specifically, the present invention provides methods and composition useful for peripheral blood stem cell mobilization. In one embodiment, a method of treating an organ transplant recipient comprises administering to the recipient a low dose of Tacrolimus in an amount sufficient to mobilize stem cells to the peripheral blood of the recipient. In a specific embodiment, the low dose of Tacrolimus is in the range of about 0.05 mg / kg to about 0.5 mg / kg.

An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or “pre-disease” state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells.

An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or ''pre-disease'' state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells.

The present invention relates to the field of biopharmaceutics and particularly relates to a use of autologous peripheral blood stem cells combined with cytokines for improving low sperm activity. Inparticular, the combination of peripheral blood stem cells and cytokines of monocyte chemoattractant protein-1 (MCP-1) and glial cell-derived neurotrophic factors (GDNF) has a synergistic treatment oran inhibition function to improve the low sperm activity, and thus the new composition or a medicinal box for the low sperm activity is provided.

The present invention relates to the TVEMF amplification of the optimized CD34+ / CD38 cell of the stem cell in the periphery and external blood of the mammalian, also relates to the composition from the TVEMF amplification cell, and a method for treating the disease or restoring the tissue with the composition.

This application relates to stem cell compositions and methods for restoring age-related tissue loss in the face and other selected areas of the body. In a first embodiment, a composition includes stem cells and hyaluronic acid as a carrier wherein the stem cells are peripheral blood stem cells, bone marrow-derived blood stem cells, or mesenchymal stem cells.

Stem cells are mobilized into the peripheral blood by a method comprising the steps of: (i) administering to an individual at least one of the following: FGF1 and FGF2, and also at least one of the following: VEGF, VEGFA and VEGF165; (ii) isolating the peripheral blood stem cells (PBSC) by apheresis; and (iii) injecting the PBSC into a patient suffering from chronic heart disease. Alternatively, gene therapy is used for the induction of the stem cells into the peripheral blood, wherein the gene therapy formulation comprises AD5FGF-4 or VEGF165 plasmid DNA. Additionally, the progress of the treatment of the chronic heart disease is monitored by using an echocardiogram unit.

The invention provides a human marrow, umbilical cord blood and peripheral blood stem cell isolation kit and an isolation method thereof. The isolation kit comprises a reagent A, a reagent B and a reagent C, wherein the reagent A is sodium chloride solution, the reagent B is sodium chloride solution with hydroxyethyl starch and a mixed antibody, and the reagent C is iodixanol operating fluid or lymphocyte separating medium. In the reagent B, a mass concentration of the hydroxyethyl starch is 5-10%, and a concentration of the mixed antibody is 4-12microgram / ml. The isolation method is characterized in that a negative selection collection method is adopted for selectively removing red blood cells, blood platelets, all plasma substances, mature blood cells and lymphocytes; all lin negative stem / progenitor cells can be collected; adoption of a mobilizing agent and plasma residuals are avoided; high-capacity isolation of marrow, umbilical cord blood and peripheral blood can be realized, and cell recovery rate reaches 85%. The isolation kit and the isolation method are especially suitable for treatment of marrow, umbilical cord blood and peripheral blood samples extracted clinically and in umbilical cord blood banks.

The invention relates to the technical field of medical instruments and discloses a peripheral blood stem cell and marrow blood reinfusion device. The peripheral blood stem cell and marrow blood reinfusion device comprises an infusion tube; the infusion tube is made of a non-toxic and harmless material; the outer side of the infusion tube is fixedly provided with a pressure control bag and a protective shell; the pressure control bag is arranged above the protective shell; a partition plate is fixedly connected to the interior of the pressure control bag; and a communication hole is formed inthe left side of the top of the partition plate. For the peripheral blood stem cell and marrow blood reinfusion device, by installing the pressure control bag on the infusion tube, when in use, as blood below the partition plate in the pressure control bag slowly flows out, a floating plate slowly descends; when a pulling rope is straightened, a floating block starts to drive a pull rod to move downwards through the pulling rope, the pull rod pulls a sliding rod, the sliding rod vertically moves downwards, and a clamping rod is driven to move rightwards to enter a moving cavity through an inclined through hole; and the upper side and the lower side of the partition plate are communicated through an L-shaped hole, blood above the partition plate flows to the lower side, and after the clamping rod moves to the position below the partition plate, the structure is reset.

The invention relates to a Chinese medicinal composition for inducing the generation of peripheral blood stem cells and a Chinese medicinal extract of the Chinese medicinal composition. The Chinese medicinal composition comprises medicinal materials in the specification, such as cinnamon bark, red paeony root, liquoric root, dried ginger, red date, Chinese angelica, astragalus and the like.

A herbal medicinal composition and a herbal medicinal extract for inducing production of peripheral blood stem cells and a method for preparing the same. The herbal medicinal composition contains herbal medicinal herbs disclosed herein such as Cinnamomum Ramulus, Paeoniae (Ovatae) Radix Rubra, Glycyrrhizae Radix, Zingiberis Rhizoma, Jujubae Fructus, Anelicae Radix, and Astragali Radix.